Centers for Disease Control awards contract to Kephera Diagnostics for point-of-care test for Taeniasis

Framingham, MA – November 13, 2018.  Kephera Diagnostics has won a $150,000 Phase I SBIR contract from the U.S. Centers for Disease Control and Prevention (CDC) to develop a point-of-care test for Taeniasis, the company announced today.  The Phase I contract will support the generation of key immunological reagents with which the test will be…

National Institutes of Health awards grant to Kephera Diagnostics for new point-of-care test for Chagas disease

Framingham, MA – September 18, 2018.  The National Institute of Allergy and Infectious Diseases, an agency of the National Institutes of Health (NIH), has awarded a two-year, $599,316 SBIR grant to Kephera Diagnostics to develop a new test for Chagas disease, the company announced today.  Under the SBIR grant program, this Phase I grant is…